Lipocine Q2 EPS $(0.68) Misses $(0.64) Estimate
Portfolio Pulse from Benzinga Newsdesk
Lipocine (NASDAQ:LPCN) reported Q2 losses of $(0.68) per share, missing the analyst consensus estimate of $(0.64) by 6.25 percent. This represents an 11.48 percent increase in losses compared to the same period last year.
August 10, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lipocine's Q2 earnings missed analyst estimates, with losses increasing compared to the same period last year.
Lipocine's Q2 earnings missed analyst estimates, which is typically a negative signal for investors. The increase in losses compared to the same period last year further exacerbates this negative sentiment. This could lead to a decrease in LPCN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100